Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence

Mohammed A Chowdhury; Jing J Zhang; Rodrigue Rizk; William C W Chen

doi:10.3389/fphys.2023.1344885

Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence

Front Physiol. 2024 Jan 9:14:1344885. doi: 10.3389/fphys.2023.1344885. eCollection 2023.

Authors

Mohammed A Chowdhury^{1

2

3}, Jing J Zhang¹, Rodrigue Rizk⁴, William C W Chen¹

Affiliations

¹ Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, Vermillion, SD, United States.
² Department of Public Health and Health Sciences, Health Sciences Ph.D. Program, School of Health Sciences, University of South Dakota, Vermillion, SD, United States.
³ Department of Cardiology, North Central Heart, Avera Heart Hospital, Sioux Falls, SD, United States.
⁴ Department of Computer Science, University of South Dakota, Vermillion, SD, United States.

Abstract

Stem/progenitor cells have been widely evaluated as a promising therapeutic option for heart failure (HF). Numerous clinical trials with stem/progenitor cell-based therapy (SCT) for HF have demonstrated encouraging results, but not without limitations or discrepancies. Recent technological advancements in multiomics, bioinformatics, precision medicine, artificial intelligence (AI), and machine learning (ML) provide new approaches and insights for stem cell research and therapeutic development. Integration of these new technologies into stem/progenitor cell therapy for HF may help address: 1) the technical challenges to obtain reliable and high-quality therapeutic precursor cells, 2) the discrepancies between preclinical and clinical studies, and 3) the personalized selection of optimal therapeutic cell types/populations for individual patients in the context of precision medicine. This review summarizes the current status of SCT for HF in clinics and provides new perspectives on the development of computation-aided SCT in the era of precision medicine and AI/ML.

Keywords: artificial intelligence; cell therapy; clinical trial; heart failure; machine learning; precision medicine; regenerative medicine; stem cells.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the U.S. Department of Defense (W81XWH2110089 to WC), the American Heart Association Career Development Award (855260 to WC), and the University of South Dakota Sanford School of Medicine (Startup Fund to WC).